Increased IL-1β expression and an aberrantly activated IL-1β signaling explicitly correlates with disease progression in a broad spectrum of local or systemic acute and chronic inflammatory diseases such as severe systemic inflammatory response syndrome, sepsis, inflammatory bowel disease and rheumatoid arthritis, and malignancies such as myeloma. This evidence concerns the gene IL1B and plasma cell myeloma.